Accentia Biopharmaceuticals (ABPIQ.PK) may emerge from Chapter 11 bankruptcy

Accentia Biopharmaceuticals (ABPIQ.PK) may emerge from Chapter 11 bankruptcy and become the next Dendreon (DNDN). On November 10, 2008 Accentia announced a reorganization plan to maximize shareholder value and to fully pay all creditors.

Well it looks like this biotech company may not only emerge from chapter 11 bankruptcy but it just might erupt! I have been following the court filings very closely unlike Adam Feurstein who just does not seem to get it when it comes to the science of BiovaxID. Maybe Feurstein needs to go back to writing about real-estate or technology in San Francisco instead of taking tips from David Miller about whether or not BiovaxID will get statistically significant results.

Any rate let’s get back to business instead of bashing the ones that don’t know how to run one. According to document 459 of the bankruptcy court of the United States of America case number 8:08-bk-17795-krm on page 6 states that if Accentia and Lazarus enter into an agreement they will do so by filing a joint agreement on or before December 14, 2009. That means if they don’t file another emergency extension we could get some really interesting news in just a few days. Therefore If that is the case this could be a catalyst that just might make provenge look like an over the counter drug.

As most of you know Accentia owns around 75 percent of the outstanding shares of Biovest (BVTI.PK). Well what does that mean to the common shareholder ? I think Bruce Springsteen can sum it all up real simply: ‘from small things (Big things one day come)’. Yes, you heard it here first. I would not be surprised to see ABPIQ.PK and BVTI.PK to merge forces as one corporation and combine their years of experience to join not one but two great life saving miracles: Revimmune and BiovaxID.

So, here you go. What you do with this information is entirely up to you. I am a shareholder in Accentia and I hope you are to. Otherwise you can hold hands with Feuerstein and take the walk of shame.

Patrick Herrmann

Patrick Herrmann is a biotech investor. I release this article to be republished.

Accentia Biopharmaceuticals Inc is in bankruptcy. Investors should be cautious when buying common stock of companies in bankruptcy. It is extremely risky and is likely to lead to financial loss.